Announcing the CloneSelect™ Single-Cell Printer™ Series. Eyewitness proof of monoclonality.
SAN JOSE, Calif., May 14, 2019 /PRNewswire/ -- Molecular Devices, LLC, a leader in protein and cell biology technologies, today announced an expansion in its partnership with cytena GmbH to launch the CloneSelect™ Single-Cell Printer™ Series in North America. Building on their success of the CloneSelect™ Single-Cell Printer™ SCP™ system, the new family evolves both the ease of use for image-based isolation and documentation of single cells and adds fluorescent sorting for further enrichment of monoclonal cell lines.
Biologics development has seen a recent boom in investment, but cloning remains a significant bottleneck in this process due to regulatory guidelines on demonstrating proof of clonality for any master cell bank (MCB). The CloneSelect™ Single-Cell Printer™ Series based on cytena's leading single-cell isolation technology enables customers to visually prove monoclonality with great efficiency, enrich viability and prevent cross-contamination.
"We are passionate about helping our customers and this new product series will help them develop and document the clonality of the cell lines customers need to advance their research." said Greg Milosevich, President at Molecular Devices. "We've listened to customer's feedback and have partnered with cytena to bring these solutions to the market quickly."
The CloneSelect™ Single-Cell Printer™ Series overcomes the draw backs of traditional methods for single-cell sorting by using gentle microfluidics to maintain high cell viability, high efficiency, and provide five images for each cell for proof of successful single-cell isolation.
"This partnership benefits the customers as well as both companies" said Jonas Schoendube, CEO at cytena. "We are excited to address more researcher's needs and to be able to reach more customers as a result of our work with Molecular Devices"
For more information, visit: moleculardevices.com/CloneSelectSCP
About cytena, GmbH
cytena is an established life science start-up. Founded in 2014 as a spin-off from the Institute for Microsystems Technology (IMTEK) at the University of Freiburg, cytena primarily sells solutions for handling biological cells. The cytena team has developed patented single-cell printerTM technology, which allows the isolation of single cells in a documented, gentle and sterile process. Single-cell printers have been manufactured in Germany and marketed worldwide since 2015. Most of the top ten pharmaceutical companies use single-cell printers to produce clonal cell lines for manufacturing antibodies.
About Molecular Devices, LLC
Molecular Devices, one of the world's leading providers of high-performance bioanalytical measurement systems, software and consumables for life science research, pharmaceutical and biotherapeutic development. Within the broad product portfolio are platforms for high-throughput screening, genomic and cellular analysis, colony selection and microplate detection. These leading-edge products enable scientists to improve productivity and effectiveness, ultimately accelerating research and discovery of new therapeutics. Molecular Devices is committed to continual development of innovative solutions for life science applications. The company is headquartered in Silicon Valley, California with offices around the globe.
Contact for Molecular Devices:
Director, Regional Marketing
Contact for cytena, GmbH:
+49 761 708890-17
SOURCE Molecular Devices